» Articles » PMID: 20482675

The Biologic Importance of Tumor-infiltrating Lymphocytes

Overview
Journal J Cutan Pathol
Publisher Wiley
Specialty Dermatology
Date 2010 May 21
PMID 20482675
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Detailed pathologic analysis has delineated a close association between intratumoral CD 8(+) cytotoxic T cells and favorable clinical outcomes in diverse cancers. Conversely, the presence at tumor sites of negative immune regulatory elements, such as FoxP 3(+) T cells (Tregs) and PD-1/PD-L1 co-stimulatory molecules, is closely associated with inferior patient survival. Together, these results indicate the importance of the balance between cytotoxic and regulatory pathways in the tumor microenvironment as a critical determinant of prognosis. This immune index also provides a framework for devising therapeutic strategies to enlarge the population of antitumor cytotoxic T cells and attenuate immune regulation. Among these approaches, vaccination with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) followed by antibody blockade of cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) provides clinical benefits for some advanced-course melanoma patients. The extent of tumor necrosis in post-treatment biopsies is linearly related to the natural logarithm of the ratio of CD 8(+) T cells to FoxP 3(+) Tregs. These findings show a concordance between the immune signature of tumor protection in endogenous and therapy-induced responses, strongly supporting Martin Mihm's original insights.

Citing Articles

Assessing the clinical utility of pre-operative neutrophil-lymphocyte ratio as a predictor of clinicopathological parameters in patients being treated for primary breast cancer.

Isik B, Davey M, Jaffer A, Buckley J, Baban C, Merrigan B Breast Cancer Res Treat. 2025; .

PMID: 39833654 DOI: 10.1007/s10549-025-07615-8.


Causal relationship between immune cell phenotypes and risk of biliary tract cancer: evidence from Mendelian randomization analysis.

Hu Y, Wang K, Chen Y, Jin Y, Guo Q, Tang H Front Immunol. 2024; 15:1430551.

PMID: 39050844 PMC: 11266158. DOI: 10.3389/fimmu.2024.1430551.


Immunotherapies for locally aggressive cancers.

Adams S, Nambiar A, Bressler E, Raut C, Colson Y, Wong W Adv Drug Deliv Rev. 2024; 210:115331.

PMID: 38729264 PMC: 11228555. DOI: 10.1016/j.addr.2024.115331.


Prognostic role of different PD-L1 expression patterns and tumor-infiltrating lymphocytes in high-grade serous ovarian cancer: a systematic review and meta-analysis.

Wang Y, Cai W, Xue Q, Zhang J, Zhou L, Xiong S Front Immunol. 2023; 14:1234894.

PMID: 37654479 PMC: 10465691. DOI: 10.3389/fimmu.2023.1234894.


Advances in Targeted Immunotherapy for Hepatobiliary Cancers.

Ruff S, Shannon A, Pawlik T Int J Mol Sci. 2022; 23(22).

PMID: 36430440 PMC: 9698563. DOI: 10.3390/ijms232213961.


References
1.
Chambers C, Sullivan T, Allison J . Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity. 1998; 7(6):885-95. DOI: 10.1016/s1074-7613(00)80406-9. View

2.
Dave S, Wright G, Tan B, Rosenwald A, Gascoyne R, Chan W . Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004; 351(21):2159-69. DOI: 10.1056/NEJMoa041869. View

3.
Chambers C, Kuhns M, Egen J, Allison J . CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001; 19:565-94. DOI: 10.1146/annurev.immunol.19.1.565. View

4.
Nishikawa H, Kato T, Tanida K, Hiasa A, Tawara I, Ikeda H . CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci U S A. 2003; 100(19):10902-6. PMC: 196900. DOI: 10.1073/pnas.1834479100. View

5.
Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K . Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007; 104(9):3360-5. PMC: 1805580. DOI: 10.1073/pnas.0611533104. View